BUFF trial: which water pill works best for liver patients?

NCT ID NCT06941415

Recruiting now Disease control Sponsor: Stacy Johnson Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether bumetanide is better than furosemide at removing excess fluid in adults hospitalized with cirrhosis. About 500 participants will receive one of the two diuretics as part of standard care. The main goal is to see which drug leads to greater weight loss by day 7, with a focus on safety and kidney function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bumetanide and furosemide (diuretics)
What this could lead to: If bumetanide works better, it could become the preferred diuretic for hospitalized cirrhosis patients, helping them lose excess fluid faster and potentially reducing serious complications.
What could go wrong: This is a pragmatic trial comparing two existing drugs, so no breakthrough is expected. The benefit may be modest, and both drugs carry risks like kidney injury or electrolyte imbalances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Edema Fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CIRRHOSIS

Contacts and locations

Locations

University of Utah Hospital
RECRUITING

Salt Lake City, Utah, 84132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.